Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,317.46
    -1,217.97 (-2.36%)
     

  • CMC Crypto 200

    1,305.91
    -90.63 (-6.49%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

AstraZeneca to start Calquence in COVID-19 trial

Reuters - UK Focus
·1-min read

April 14 (Reuters) - AstraZeneca Plc said on Tuesday that it would start a clinical trial to assess the potential of Calquence in the treatment of the exaggerated immune response associated with COVID-19 infection in severely ill patients.

Calquence is already approved for the treatment of adult patients with chronic lymphocytic leukaemia in the United States and a number of other countries.

The goal of the trial is to evaluate the effectiveness and safety of adding the drug to best supportive care to reduce mortality and the need for assisted ventilation in patients with life-threatening COVID-19 symptoms, the British drugmaker said.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; editing by Patrick Graham)